Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study

BACKGROUND: Evidence on PD-1/PD-L1-directed immune checkpoint inhibitor (ICI) therapy for advanced non-small-cell lung cancer (NSCLC) is mainly based on clinical trials in first- or second-line settings. OBJECTIVE: We aimed to investigate response and prognostic factors with special regard to third-...

Descripción completa

Detalles Bibliográficos
Autores principales: Lang, David, Huemer, Florian, Rinnerthaler, Gabriel, Horner, Andreas, Wass, Romana, Brehm, Elmar, Akbari, Kaveh, Granitz, Marcel, Hutarew, Georg, Kaiser, Bernhard, Greil, Richard, Lamprecht, Bernd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875512/
https://www.ncbi.nlm.nih.gov/pubmed/31654203
http://dx.doi.org/10.1007/s11523-019-00679-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875512/
https://www.ncbi.nlm.nih.gov/pubmed/31654203
http://dx.doi.org/10.1007/s11523-019-00679-9

Ejemplares similares